No Data
No Data
A Look Ahead: Allurion Technologies's Earnings Forecast
Earnings Preview: ALUR to Report Financial Results Pre-market on November 13
TD Cowen Maintains Allurion Technologies(ALUR.US) With Buy Rating, Maintains Target Price $2
Allurion Technologies' Platform Shows Promising Weight Loss Results, Boosting Confidence in Commercial Potential
Express News | Allurion Technologies Announced Data From Over 19,000 Patients Between 2018-2023 That Used Its Program Showing An Average Loss Of 12.2% Of Total Body Weight
Allurion Presents The Second Abstract Reports On Outcomes Of The Allurion Program For 27 Patients Previously Treated With Liraglutide Who Did Not Respond To Their GLP-1 Treatment. 55% Had No Weight Loss And 45% Had Weight Loss Of Less Than 5% With...
loading...
No Data
No Data